A niche blog dedicated to the issues that arise when supplementary protection certificates (SPCs) extend patents beyond their normal life -- and to the respective positions of patent owners, investors, competitors and consumers. The blog also addresses wider issues that may be of interest or use to those involved in the extension of patent rights. You can email The SPC Blog here

Wednesday, 25 January 2012

The WSJ debate: what's your view?

Writing on the IPKat weblog -- a general interest intellectual property blog which many readers of this blog do not get to read -- England-based Australian lawyer Catherine Lee has posted this summary of "Should Patents on Pharmaceuticals Be Extended to Encourage Innovation?", a Wall Street Journal feature in the form of a debate between Josh Bloom (director of Chemical and Pharmaceutical Sciences at the American Council on Science) and Els Torreele (director of the Access to Essential Medicines Initiative of the Open Society Foundation's Public Health Program) as to whether pharma patents should be incentivised by longer patents or funded through the infusion of funds within a regulatory environment.

Readers who wish to give Catherine the benefit of their opinion are invited to do so.

No comments: